



Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Dieter Weinand to become President of Bayer HealthCare Pharmaceuticals

Leverkusen, June 5, 2014 – Dieter Weinand (53), President Global Commercialization & Portfolio Management at Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA, will become President of Bayer HealthCare Pharmaceuticals effective August 1, 2014 and at the same time join the Executive Committee of Bayer HealthCare.

"We welcome Dieter Weinand to our management team. Based on his extensive commercial experience in the pharmaceutical industry, Dieter Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio," said Olivier Brandicourt, CEO of Bayer HealthCare.

Dieter Weinand has more than 25 years of experience in various commercial operative and strategic executive roles in the pharmaceutical industry. He has been responsible for different markets such as Asia-Pacific, Europe, Middle East, Africa, Latin America and the USA at companies including Pfizer and Bristol-Myers Squibb as well as for the marketing of products in different therapeutic areas such as cardiology, oncology, pulmonology, dermatology, immunology and inflammation.

He will join Bayer HealthCare from Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA, where he is currently responsible as President, Global Commercialization for a \$13 billion revenue healthcare business.

Weinand earned a M.S. in Pharmacology/Toxicology from Long Island University, New York, as well as a B.A. in Biology from Concordia College in New York.

Dieter Weinand, who was born in Boppard, Germany, is married and has three children.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)

Dr. Jürgen Beunink (+49-214-30-65742)

Peter Dahlhoff (+49-214-30-33022)

Judith Nestmann (+49-214-30-66836)

Constance Spitzer (+49-214-30-33021)

Dr. Olaf Weber (+49-214-30-33567)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.